Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-22T15:26:01.587Z Has data issue: false hasContentIssue false
  • English
  • Français

A new Pseudomonas vaccine: Preliminary trial on human volunteers

Published online by Cambridge University Press:  15 May 2009

R. J. Jones ,
E. A. Roe ,
E. J. L. Lowbury ,
J. J. Miler  and
J. F. Spilsbury
R. J. Jones
Affiliation:
M.R.C. Industrial Injuries and Burns Research Unit, Birmingham Accident Hospital
E. A. Roe
Affiliation:
M.R.C. Industrial Injuries and Burns Research Unit, Birmingham Accident Hospital
E. J. L. Lowbury
Affiliation:
M.R.C. Industrial Injuries and Burns Research Unit, Birmingham Accident Hospital
J. J. Miler
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
J. F. Spilsbury
Affiliation:
The Wellcome Research Laboratories, Beckenham, Kent
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Fifteen healthy volunteers were given three weekly subcutaneous injections of a new polyvalent Pseudomonas aeruginosa vaccine (PEV-01). Four doses – 1·0 RHD (manufacturer's recommended human dose), 0·75 RHD, 0·5 RHD and 0·1 RHD – were used in separate groups of volunteers. Blood samples taken before each of the injections and one taken 7 days after the last injection were examined for immune response to the vaccine and for possible adverse clinical, biochemical and haematological effects.

Raised titres of antibody in serum of volunteers given 0·5–1·0 RHD vaccine were shown, often by the seventh day, in passive haemagglutination tests against all of the 16 serotypes of Ps. aeruginosa represented in the vaccine; serum from volunteers who received 0·1 RHD usually showed a reduced antibody titre. Tests of mouse protection by serum against intraperitoneal challenge with Ps. aeruginosa P14 showed increased titres of mouse protective antibody in the blood of volunteers given 1·0, 0·75 or 0·5 RHD of vaccine but a reduced mouse-protective titre in two out of three sera from volunteers given 0·1 RHD vaccine. There was a suggestion of enhanced phagocytic ingestion and intracellular killing of two strains of Ps. aeruginosa by the blood of vaccinated volunteers, and more definite enhancement of ingestion of inert latex particles, which were less well ingested than were the bacterial cells by phagocytes from unvaccinated volunteers.

Apart from slight or moderate local reactions and a transient rise of temperature in some volunteers, there were no clinical, biochemical or haematological abnormalities in the vaccinated volunteers.

Type
Research Article
Information
Journal of Hygiene , Volume 76 , Issue 3 , June 1976 , pp. 429 - 439
Copyright
Copyright © Cambridge University Press 1976

References

REFERENCES

Alexander, J. W. & Fisher, M. W. (1973). Immunisation against Pseudomonas in burn disease. In Gram-negative Bacterial Infections(ed. Urbaschek, B., Urbaschek, K. and Neter, E.), p. 489. Vienna: Springer-Verlag.Google Scholar
Feller, I. (1966). In Research in Burns(ed. Wallace, A. B. and Wilkinson, A. W.), p. 470. Edinburgh: Livingstone.Google Scholar
Fox, J. E. & Lowbury, E. J. L. (1953). Immunity and antibody to Pseudomonas pyocyanea in rabbits. Journal of Pathology and Bacteriology 65, 533.CrossRefGoogle ScholarPubMed
Gordon, P. A., Stuart, J., Lee, T. R., Breeze, G. R. & Pugh, R. N. H. (1975). The cytocentrifuge NBT test. Journal of Clinical Pathology 28, 674.CrossRefGoogle ScholarPubMed
Hoechst Pharmaceuticals (Sept. 1972). Behringwerke Products for the Quantitative Determination of Plasma Proteins, p. 11.Google Scholar
Jones, R. J. (1968). Protection against Pseudomonas aeruginosa infection by immunisation with fractions of culture filtrates ofPs. aeruginosa. British Journal of Experimental Pathology 49, 411.Google Scholar
Jones, R. J. (1971). Early protection by vaccines in burns. British Journal of Experimental Pathology 52, 100.Google ScholarPubMed
Jones, R. J. (1972). Specificity of early protective responses induced by pseudomonas vaccines. Journal of Hygiene 70, 343.CrossRefGoogle ScholarPubMed
Jones, R. J. & Dyster, R. E. (1973). The role of polymorphonuclear leucocytes in protecting mice vaccinated against Pseudomonas aeruginosa infections. British Journal of Experimental Pathology 54, 416.Google Scholar
Jones, R. J., Hall, M. & Ricketts, C. R. (1972). Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine. Immunology 23, 889.Google ScholarPubMed
Jones, R. J., Jackson, D. M. & Lowbury, E. J. L. (1966). Antiserum and antibiotic in the prophylaxis of burns againstPseudomonas aeruginosa. British Journal of Plastic Surgery 19, 43.CrossRefGoogle ScholarPubMed
Jones, R. J., Lilly, H. A. & Lowbury, E. J. L. (1971). Passive protection of mice against Pseudomonas aeruginosa by serum from recently vaccinated mice. British Journal of Experimental Pathology 52, 264.Google ScholarPubMed
Jones, R. J. & Lowbury, E. J. L. (1972). Early protection by vaccines against Pseudomonas aeruginosa colonising burns. British Journal of Experimental Pathology 53, 659.Google ScholarPubMed
Jones, R. J. & Roe, E. A. (1975). Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent pseudomonas vaccine. British Journal of Experimental Pathology 56, 34.Google ScholarPubMed
Jones, R. J., Roe, E. A. & Dyster, R. E. (1975). Detection of endotoxins with the Limulus test in burned and unburned mice infected with different species of Gram-negative bacteria. Journal of Hygiene 75, 99.CrossRefGoogle ScholarPubMed
Levin, J. & Bang, F. B. (1968). Clottable protein in Limulus: its localisation and kinetics of its coagulation by endotoxin. Thrombosis et Diathesis Haemorrhagica 19, 186.Google ScholarPubMed
Lillie, R. D. (1965). Histopathologic Technic and Practical Histochemistry, 3rd ed., p. 368. McGraw Hill.Google Scholar
Lowbury, E. J. L. & Jones, R. J. (1975). Treatment and prophylaxis for pseudomonas infections. In Resistance of pseudomonas aeruginosa(ed. Brown, M. R. W.), p. 237. London: John Wiley.Google Scholar
Markley, K. & Smallman, E. (1968). Protection by vaccination against Pseudomonas aeruginosa infection after thermal injury. Journal of Bacteriology 96, 867.CrossRefGoogle ScholarPubMed
Miler, J., Spilsbury, J. F., Jones, R. J., Roe, E. A. & Lowbury, E. J. L. (1976). (To be published.)Google Scholar
Miles, A. A., Misra, S. S. & Irwin, J. O. (1938). The estimation of the bactericidal power of the blood. Journal of Hygiene 38, 732.Google ScholarPubMed
Roe, E. A. & Jones, R. J. (1971). The NBT response of polymorphonuclear leucocytes in burned mice. Burns 1, 301.CrossRefGoogle Scholar
Young, L. S. & Armstrong, D. (1972). Human immunity to Ps. aeruginosa: in vitro interaction of bacteria, polymorphonuclear leucocytes and serum factors. Journal of Infectious Diseases 126, 257.CrossRefGoogle Scholar